Novavax, Inc.
9.70USD
-0.2900 (-2.90%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NVAX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57 | 140 | 147 | 70 | 239 | 667 | 88 | 85 |
| Cost of Revenue | 14 | 31 | 22 | 21 | 15 | 14 | 37 | 61 |
| Gross Profit | 42 | 109 | 125 | 49 | 224 | 653 | 52 | 24 |
| Operating Income | -55 | -15 | 14 | -178 | 101 | 516 | -131 | -134 |
| Net Income | -53 | -9 | 18 | -202 | 107 | 519 | -81 | -121 |
| EPS (Diluted) | -$0.32 | -$0.06 | $0.05 | -$1.25 | $0.62 | $2.93 | -$0.52 | -$0.76 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)